PATENT Customer No. 22,852 New Attorney Docket No. 08201.0024-01000

Rachel Venturi

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Fabienne MacKay et al.	) Group Art Unit: 1646
Application No.: 10/045,574	) Examiner: Not yet assigned
Filed: November 7, 2001	) ) CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8
For: BAFF, INHIBITORS THEREOF AND THEIR USE IN THE MODULATION OF B-CELL RESPONSE AND TREATMENT	I hereby certify that this correspondence is being deposited with the United States Postal Services under 37 C.F.R. § 1.8 on December 16, 2002 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

OF AUTOIMMUNE DISORDERS

Commissioner for Patents Washington, DC 20231

Attention: **BOX MISSING PARTS** 

Sir:

## RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING **NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants submit a substitute Sequence Listing in both computer readable form and paper form for filing in this application and a copy of the Notice to Comply.

Please amend the specification to delete the Sequence Listing previously filed and to insert the attached Sequence Listing.

Applicants' representative verifies that the Sequence Listing in computer readable form is identical to the paper copy and that no new matter has been added through this submission.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

Please associate the enclosed materials with the application, grant any extensions of time required to enter this response, and charge any required fees to deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.


Dated: December 16, 2002

Leslie A. McDonell Reg. No. 34,872

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com









Date Mailed: 10/16/2002

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/045,574

Timothy P. Linkkila BIOGEN, INC.

14 Cambridge Center Cambridge, MA 02142 11/07/2001

Fabienne MacKay

**A070 US CP** 

**CONFIRMATION NO. 9312** 

**FORMALITIES LETTER** 

OC000000008959783\*

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES** 

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply. BIOGEN, INC. - IP DE

OCT 21 20°

REFERRED TO **MOLED BA** 

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY